Injection Human Interleukin 2 Market Report 2026

The injection human interleukin 2 market size has grown rapidly in recent years. It will grow from $1.21 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to early success of cytokine-based immunotherapy, rising cancer incidence, advancement in recombinant protein production, increased hospital-based oncology treatments, regulatory approvals for il-2 therapies.

The injection human interleukin 2 market size is expected to see rapid growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to growth in cancer immunotherapy pipelines, increasing use of il-2 with checkpoint inhibitors, advancements in targeted immune activation, rising investment in biologic oncology drugs, expansion of precision immunotherapy approaches. Major trends in the forecast period include increasing use of il-2 in combination immunotherapies, growing adoption of recombinant human interleukin 2, expansion of il-2 applications in oncology, rising focus on dose optimization to reduce toxicity, increasing clinical research in immune modulation.

The growing emphasis on personalized medicine is expected to drive the expansion of the injection human interleukin 2 market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s unique genetic profile, lifestyle, and environment. The rising demand for personalized medicine is fueled by advancements in genetic testing, which enable more precise diagnoses and targeted therapies tailored to each patient, enhancing outcomes and minimizing side effects. Injection human interleukin 2 contributes to personalized medicine by allowing its incorporation into customized immunotherapy regimens, where IL-2 is administered according to a patient’s specific immune profile to optimize therapeutic efficacy and reduce adverse effects. For example, in February 2024, a report by the Personalized Medicine Coalition, a US-based non-profit organization, noted that the FDA approved 16 novel customized medicines for patients with rare diseases in 2023, compared to only six in 2022. Consequently, the increasing focus on personalized medicine is expected to support the growth of the injection human interleukin 2 market.

Major companies in the injection human interleukin-2 market are concentrating on developing innovative therapies, such as low-dose interleukin-2, to enable longer-term treatment regimens. Low-dose interleukin-2 involves administering small amounts of IL-2 to selectively stimulate regulatory T cells, promoting immune tolerance while minimizing inflammation and adverse effects. For example, in October 2024, Coya Therapeutics Inc., a US-based biotechnology company, announced the results of a double-blind study evaluating subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer’s disease (AD). The study successfully achieved its primary and secondary endpoints, enhancing regulatory T cells (Tregs) without affecting T effector lymphocytes. Exploratory outcomes indicated that administering low-dose IL-2 every four weeks stabilized cognition, improved cerebrospinal fluid (CSF) soluble Aβ42 levels, and maintained CSF Neurofilament Light Chain (NfL) levels. These results reinforce the potential of Treg modulation as a therapeutic approach for neurodegenerative diseases, particularly Alzheimer’s. COYA 301, an investigational low-dose IL-2 therapy, is designed to enhance Treg function via subcutaneous administration to modulate inflammation.

In May 2023, Iovance Biotherapeutics, a U.S.-based provider of T-cell immunotherapies, including tumor-infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL) therapies, acquired Proleukin (aldesleukin) from Clinigen Limited for £166.7 million upfront, along with £41.7 million in milestone payments and global sales royalties. Through this acquisition, Iovance aimed to secure its IL-2 supply chain, lower costs associated with clinical trials and manufacturing of TIL therapies, and establish a stable revenue stream. Clinigen Limited is a UK-based company that offers interleukin-2 cytokine therapy to enhance T-cell activity in adoptive immunotherapy treatments.

Major companies operating in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Merck & Co. Inc., Bristol Myers Squibb, Sanofi S.A., Pfizer Inc., Amgen Inc., Nektar Therapeutics, Synthekine Inc., Xilio Therapeutics Inc., Iovance Biotherapeutics Inc., Clinigen Group plc, BeiGene Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Beijing SL Pharmaceutical Co. Ltd., Shandong Quangang Pharmaceutical Co. Ltd., PeproTech Inc., Qkine Ltd., Akron Biotechnology LLC, Thermo Fisher Scientific Inc.

North America was the largest region in the injection human interleukin 2 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injection human interleukin 2 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the injection human interleukin 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the injection human interleukin 2 market by increasing costs associated with imported biologic production inputs, fermentation equipment, and cold-chain logistics. These effects are most prominent in recombinant human interleukin 2 products and oncology applications, particularly in North America, Europe, and Asia-Pacific regions. Higher tariffs have contributed to elevated treatment costs in hospital and clinic settings. On the positive side, tariffs have encouraged domestic biologics manufacturing and strengthened regional supply chain resilience for immunotherapy drugs.

The injection human interleukin 2 market research report is one of a series of new reports that provides injection human interleukin 2 market statistics, including injection human interleukin 2 industry global market size, regional shares, competitors with a injection human interleukin 2 market share, detailed injection human interleukin 2 market segments, market trends and opportunities, and any further data you may need to thrive in the injection human interleukin 2 industry. This injection human interleukin 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Injection human interleukin 2 is a biologic medication mainly used in immunotherapy to promote the growth and activity of immune cells, particularly T cells and natural killer (NK) cells. It is a recombinant form of the naturally occurring cytokine interleukin-2, which plays a crucial role in regulating immune responses. By strengthening the body’s innate immune defense mechanisms, IL-2 injections help improve the recognition and destruction of cancer cells.

The primary product types of injection human interleukin 2 include recombinant human interleukin 2 and natural human interleukin 2. Recombinant human interleukin 2 is an engineered form of interleukin 2 produced using recombinant deoxyribonucleic acid technology. It can be administered via subcutaneous, intravenous, or intramuscular injection and is distributed through direct sales, pharmacies, and online channels. It is used in oncology, immunotherapy, and autoimmune disease treatments by various end users, including hospitals, clinics, research institutes, and others.

The injection human interleukin 2 market consists of sales of monoclonal antibodies, checkpoint inhibitors, cancer vaccines and immune modulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.